CYP17A1/HDAC6-IN-1
CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM, respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity[1].
Product Specifications
CAS Number
3047489-22-2
UNSPSC
12352005
Target
Cytochrome P450; HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cyp17a1-hdac6-in-1.html
Solubility
10 mM in DMSO
Smiles
C[C@@]12[C@](CC=C2C3=CN=CC=C3)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5(C(C[C@H](CC5)OC(CCCCCC(NO)=O)=O)=CC4)C
Molecular Formula
C31H42N2O4
Molecular Weight
506.68
References & Citations
[1]Ram Sharma, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Lett. 2024 Feb 2:586:216666.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP17A1; HDAC6
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680352-100 1x 100 µL
CD31 / PECAM-1 (158-2B3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941782-500 1x 500 µL
Thrombomodulin / CD141 (Endothelial Cell Marker) (THBD/1782), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details